95 related articles for article (PubMed ID: 8823342)
21. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
22. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
23. Adaptive control with feedback of suramin using intermittent infusions.
Figg WD; Stevens JA; Cooper MR
J Clin Oncol; 1994 Jul; 12(7):1523-4. PubMed ID: 8021743
[No Abstract] [Full Text] [Related]
24. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
26. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
28. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Mahalingam D; Nemunaitis JJ; Malik L; Sarantopoulos J; Weitman S; Sankhala K; Hart J; Kousba A; Gallegos NS; Anderson G; Charles J; Rogers JM; Senzer NN; Mita AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1241-50. PubMed ID: 25304209
[TBL] [Abstract][Full Text] [Related]
30. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
31. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel in combination with fluorouracil for advanced solid tumors.
Burris HA
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):50-2. PubMed ID: 9364544
[TBL] [Abstract][Full Text] [Related]
33. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
34. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
35. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
38. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.
Nuessler V; Scheulen ME; Oberneder R; Kriegmair M; Goebel KJ; Rathgeb F; Wurst W; Zech K; Wilmanns W
Eur J Med Res; 1997 Feb; 2(2):55-61. PubMed ID: 9085015
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]